This study proposes to test if the study drug triapine is an effective radiation sensitizer that can be safely combined with peptide receptor radionuclide therapy (PRRT) and can improve antitumor activity of the PRRT Lutetium Lu 177 Dotatate for well-differentiated somatostatin receptor-positive neuroendocrine tumors.

This study aims to learn and evaluate the relationship between vocal register, pitch, and loudness by investigating how vocal pitch changes with variations in loudness.

Participants will be required to sing in both chest register and head registers, with their vocal pitch being measured twice. They will also undergo a free laryngoscopy.

The total time commitment is approximately 1 hour and those who complete the study will receive $100 for their participation.

This clinical trial is for men and women who have an advanced cancer that has not responded or has stopped responding to treatment with a class of drugs called programmed cell death protein-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) inhibitors.
   

The purpose of this study is to provide real world information about an implantable device called “eCoin” to treat urgency urinary incontinence for people experiencing the accidental leakage of urine.

For those not well treated by drugs and other alternatives, percutaneous tibial nerve stimulation (PTNS) and sacral nerve stimulation (SNS) are other therapies approved in the United States by the Food and Drug Administration (FDA). In the U.S., PTNS is approved for treatment of overactive bladder and the associated symptoms described above in the Introduction.

This study is being conducted to evaluate if Rosuvastatin is safe and can help people living with cirrhosis lead longer, healthier lives.

The purpose of this study is to see if human immunodeficiency virus (HIV) antiretroviral therapy (ART) medicines continue to work well in transgender women (TW) and other individuals identifying as female or transfeminine but with male sex assigned at birth when taken with feminizing hormone therapy (FHT), also known in this study as estradiol. The study will determine if TW remain undetectable while receiving FHT for 48 weeks. Additionally, it will assess if hormone levels change based on the type of HIV medication taken. 

This clinical trial is for adult participants who have triple-negative breast cancer (TNBC) without pathological complete response (pCR), as determined at the time of their surgery following neoadjuvant therapy. The term TNBC refers to the fact that the cancer cells do not have estrogen or progesterone receptors (ER or PR) and also do not make any or much of the protein called HER2 (human epidermal growth factor receptor 2). The term pCR refers to the absence of all signs of cancer in tissue removed during surgery.

This clinical trial is for men and women with newly diagnosed with acute Graft vs Host Disease (GvHD).

The purpose of this study is to evaluate if CYP-001 can be effective to treat GvHD that has not responded to steroids.

The study drug used in this study (CYP-001) is experimental. This means that it is not an approved treatment for high-risk acute GvHD by the U.S. Food and Drug Administration (FDA) or anywhere in the world.

Almost 10 million children in the United States are affected by at least one allergic disease and the rates of allergy are rising. Prior public health research shows that children born to individuals who are anxious during pregnancy have higher rates of allergy, but the cause behind this occurrence is not known.

This study is being done to look at the safety of delivering pulsed electric fields (PEF) to tumor(s) in patients with metastatic cancer within the lungs requiring biopsy, or tumor(s) from stage IV non-small cell lung cancer (NSCLC) requiring biopsy, who have not previously had treatment for the tumor(s), who are not surgical candidates, and who are considered eligible for first-line standard-of-care (SOC) cancer therapy.